

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 31, 2017 (the “**Prospectus**”) issued by WuXi Biologics (Cayman) Inc. (the “**Company**”).*

*This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for Shares or any securities. Potential investors should read the Prospectus for detailed information about the Global Offering illustrated below before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “Qualified Institutional Buyers” and “Qualified Purchasers” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.*

## **WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION**

### **FULL EXERCISE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was fully exercised by the Joint Global Coordinators (on behalf of the International Underwriters) on June 14, 2017 in respect of 28,947,000 additional new Shares (the “**Over-allotment Shares**”), representing approximately 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option, to facilitate the return to WuXi Biologics Holdings Limited (“**Biologics Holdings**”) of 28,947,000 borrowed Shares which were used to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$20.60 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering. A further announcement will be made by the Company after the end of the stabilization period.

## **FULL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was fully exercised by the Joint Global Coordinators (on behalf of the International Underwriters) on June 14, 2017 in respect of 28,947,000 additional new Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option, to facilitate the return to Biologics Holdings of 28,947,000 borrowed Shares which were used to cover over-allocations under the International Offering. The Over-allotment Shares will be issued and allotted by the Company at HK\$20.60 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on June 19, 2017.

Pursuant to the Stock Borrowing Agreement, the Stabilizing Manager has borrowed 28,947,000 Shares from Biologics Holdings to cover over-allocations under the International Offering. The Over-allotment Shares will be used to facilitate the return in full to Biologics Holdings of the 28,947,000 borrowed Shares.

The shareholding structure of the Company immediately before and immediately after the allotment and issue by the Company of the Over-allotment Shares is as follows:

<b>Shareholders</b>	<b>Immediately before the allotment and issue of the Over-allotment Shares</b>		<b>Immediately after the allotment and issue of the Over-allotment Shares</b>	
	<i>Number of Shares</i>	<i>Approximate % of the Company's issued share capital</i>	<i>Number of Shares</i>	<i>Approximate % of the Company's issued share capital</i>
Biologics Holdings	855,436,988	75.43%	855,436,988	73.55%
G&C VII Limited	54,602,361	4.81%	54,602,361	4.69%
I-Invest World Ltd	2,173,775	0.19%	2,173,775	0.19%
i-growth Ltd	1,778,544	0.16%	1,778,544	0.15%
Dr. Zhisheng Chen	711,418	0.06%	711,418	0.06%
Mr. Edward Hu	1,441,500	0.13%	1,441,500	0.12%
Other Management	24,990,971	2.20%	24,990,971	2.15%
Public Shareholders	<u>192,982,500</u>	<u>17.02%</u>	<u>221,929,500</u>	<u>19.08%</u>
<b>Total</b>	<u><u>1,134,118,057</u></u>	<u><u>100.00%</u></u>	<u><u>1,163,065,057</u></u>	<u><u>100.00%</u></u>

As shown in the shareholding structure of the Company set out above, immediately before the allotment and issue of the Over-allotment Shares, approximately 17.02% of the issued share capital of the Company was held by public Shareholders, and approximately 19.08% of the issued share capital of the Company will be held by public Shareholders immediately after the allotment and issue of the Over-allotment Shares. The Company continues to satisfy the minimum public float percentage accepted by the Stock Exchange as described in the section headed “Waivers from Strict Compliance with the Listing Rules - Public Float Requirements” in the Prospectus.

The Company estimates that it will receive additional net proceeds of approximately HK\$575.4 million from the issue of the Over-allotment Shares, after deducting the commissions and other offering expenses payable by the Company in relation to the exercise of the Over-allotment Option. The Company intends to apply the additional net proceeds to satisfy its additional capital expenditure needs as set out in the section headed “Future Plans and Use of Proceeds — Use of Proceeds” in the Prospectus.

A further announcement will be made by the Company after the end of the stabilization period in connection with the Global Offering pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board of Directors  
**Dr. Ge Li**  
*Chairman*

Hong Kong, June 14, 2017

*As of the date of this announcement, the Board of Directors comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.*

*\* For identification purpose only*